TOKYO, Mar 30 (Pulse News Wire) – TMS CO.,LTD. (4891.T) outlined its growth strategy centered around clinical development pipelines, particularly focusing on compounds such as TMS-007 and TMS-008.
TMS-007, which achieved a Gold-Standard endpoint in Phase 2a for acute ischemic stroke, showed potential to surpass the sales of FDA-approved drug t-PA. The company plans to complete Phase 2 enrollment by December 08, 2025. In addition, TMS-008, targeting inflammatory diseases, completed Phase 1 trials and is set to begin Phase 2a trials in the second half of 2026.
The company also secured financing through a rights issue in March 2025, raising a total of ¥639 million. Financially, TMS reported a reduction in operating expenses compared to initial forecasts, resulting in a decrease in operating losses by 12 months' equivalent to the previous year. Cash flow was bolstered by funding activities, leading to a net cash balance of 2,781 million yen at the end of the fiscal year ending December 31, 2025.
Looking ahead, TMS expects continued investment in research and development, aiming to strengthen its pipeline and secure stable financial foundations.
🔴 Confidence: Review recommended AI-translated content.